AntidepressantPill.com

Press release content from Globe Newswire. The AP news staff was not involved in its creation. CLEARWATER, Fla., March 06, 2019 (GLOBE NEWSWIRE) — The Food and Drug Administration (FDA) is considering approving Johnson & Johnson’s (J&Js) new nasal spray antidepressant, esketamine (brand name Spravato), after an FDA advisory committee voted on February 12, 2019 in its favor. The drug...

(RxISK.org) – Maybe you heard the exciting news last month about a game-changing new treatment for depression. It offered new hope to millions who were not helped by existing drugs, the headlines said – the first real breakthrough in depression treatment since Prozac, some thirty years ago. The product was Janssen’s esketamine nasal inhaler, described as (RxISK.org) – Maybe you...

/PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic… TITUSVILLE, N.J. , Feb. 12, 2019 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee jointly voted...

/PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today announced the submission of a New Drug Application (NDA) to the U.S…. TITUSVILLE, N.J. , Sept. 4, 2018 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for esketamine...